[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340489-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-340489-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","mediator-kinase-inhibitors-suppress-triple-negative-breast-cancer-growth-and-extend-tumor-suppression-by-mtor-and-akt-inhibitors-research-article","Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors - Research article","","Triple-negative breast cancers (TNBC) rely mainly on chemotherapy and lack clinically validated therapeutic targets, partly because treatment resistance is driven by tumor transcriptomic plasticity. The study investigates how CDK8/19 Mediator kinase inhibitors influence TNBC tumor growth and responses to mTOR and AKT inhibitors. Unlike many drugs, CDK8/19 inhibition suppresses growth in vivo even when in vitro responses are limited, extends host survival in lung metastasis models, and synergizes with everolimus and capivasertib. Transcriptomic profiling shows combination-specific gene expression changes in tumor and stromal cells.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mediator-kinase-inhibitors-suppress-triple-negative-breast-cancer-growth-and-extend-tumor-suppression-by-mtor-and-akt-inhibitors-research-article/340489/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mediator-kinase-inhibitors-suppress-triple-negative-breast-cancer-growth-and-extend-tumor-suppression-by-mtor-and-akt-inhibitors-research-article/340489.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why have PI3K/AKT/mTOR pathway inhibitors been ineffective in TNBC clinical trials?","Question",{"text":63,"@type":64},"Adaptive drug resistance has limited clinical efficacy, driven largely by transcriptomic plasticity in TNBC that enables transcriptional adaptation to therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the main effect of CDK8/19 inhibitors on TNBC models in vivo versus in vitro?",{"text":68,"@type":64},"All tested TNBC human models responded to CDK8/19 inhibitors in vivo, including patient-derived xenografts, even when they did not respond in vitro.",{"name":70,"@type":61,"acceptedAnswer":71},"How do CDK8/19 inhibitors interact with mTOR and AKT inhibitors?",{"text":72,"@type":64},"CDK8/19 inhibitors synergized with everolimus (mTORC1 inhibitor) and potentiated tumor suppression with capivasertib (pan-AKT inhibitor) in long-term in vivo studies.",{"name":74,"@type":61,"acceptedAnswer":75},"What did transcriptomic analyses reveal about drug adaptation and combination mechanisms?",{"text":76,"@type":64},"Drug adaptation to everolimus in vivo was associated with major transcriptional changes in both tumor and stromal cells, and combining everolimus with a CDK8/19 inhibitor counteracted many of these changes with combination-specific gene expression effects.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},340489,1790653448,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \n OPEN ACCESS  \nMediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors  \nXiaokai Dinga , Jiaxin Lianga, Amanda C. Sharkoa, Thomas A. Hilimirea, b, Jing Lia , Jürgen Loskutovc, Zachary T. Macka, Hao Jia , Gary P. Schoolsa, Chao Caid, Elena N. Pugachevac, Mengqian Chena, b,1, Igor B. Roninsona,1, and Eugenia V. Broudea,1  \nEdited by Myles Brown, Dana-Farber Cancer Institute, Boston, MA; received July 18, 2024; accepted October 18, 2024  \nTriple-negative breast cancers (TNBC) are treated primarily by chemotherapy and lack clinically validated therapeutic targets. In particular, inhibitors of the PI3K/AKT/mTOR pathway, abnormally activated in many breast cancers, failed to achieve clinical efficacy in TNBC due to the development of adaptive drug resistance, which is largely driven by the transcriptomic plasticity of TNBC. Expression of CDK8/19 Mediator kinases that control transcriptional reprogramming correlates with relapse-free survival and treatment failure in breast cancer patients, including TNBC. We now investigated how CDK8/19 inhibitors affect the growth ofTNBC tumors and their response to mTOR and AKT inhibitors. In contrast to the effects of most anticancer drugs, all the tested human TNBC models (including patient-derived xenografts) responded to CDK8/19 inhibitors in vivo even when they did not respond in vitro. Furthermore, CDK8/19 inhibition extended the host survival of established lung metastases in a murine TNBC model, where the primary tumors were not significantly affected. CDK8/19 inhibitors synergized with an mTORC1 inhibitor everolimus and a pan-AKT inhibitor capivasertibin vitro and strongly potentiated these drugs in long-term in vivo studies. Transcriptomic analysis of tumors that responded or became adapted to everolimus revealed that drug adaptation in vivo was associated with major transcriptional changes in both tumor and stromal cells. Combining everolimus with a CDK8/19 inhibitor counteracted many of these changes and induced combination-specific effects on the expression of multiple genes that affect tumor growth. These results warrant the exploration of CDK8/19 Mediator kinase inhibitors as a new type of drugs for TNBC therapy.  \ntriple negative breast cancer | CDK8 | mediator kinase | mTOR | metastasis  \nBreast cancers (BrCa) that are negative for estrogen receptor (ER), progesterone receptor, and HER2 are broadly classified as triple-negative breast cancer (TNBC). TNBCs are highly metastatic and lack clinically validated therapeutic targets; their treatment is still based largely on conventional chemotherapy, which is toxic and rarely curative. Many targeted drugs and immunotherapies are undergoing clinical trials but have not yet shown a clear benefit forTNBC, except for PARP and checkpoint inhibitors that benefit a small number of patients (1, 2). In particular, while the PI3K/AKT/mTOR signaling pathway is overactivated in at least half ofTNBCs, inhibitors of this pathway have not shown clinical efficacy in TNBC trials (3) . The key obstacle to achieving sustained therapeutic efficacy is the development of treatment resistance. It is now understood that the transcriptomic plasticity of tumor cells promotes therapy resistance via nongenetic (transcriptional) adaptation to treatment (4). The transcriptomic plasticity also enables the metastatic growth and its associated resistance of metastatic cells to different therapies (5). As a result, many drugs, while efficacious against primary tumors, have no effect in a metastatic setting (6). A therapeutic strategy aimed at transcriptomic plasticity per se could have a critical impact on the treatment of metastatic disease and the prevention of the adaptive drug resistance.  \nA novel class of anticancer drugs under clinical development target CDK8 and CDK19 Mediator kinases ([clinicaltrials.gov](clinicaltrials.gov) NCT03065010, NCT04021368, N","cbCaijzHW98fLpyq","https://ap.wps.com/l/cbCaijzHW98fLpyq","pdf",1676189,"English","# Background: TNBC resistance and transcriptomic plasticity\n# Study rationale and target biology (CDK8/19 Mediator kinases)\n# Key findings: in vivo efficacy, metastasis survival benefit, and synergy\n## Combination effects with everolimus and capivasertib\n# Transcriptomic analysis of responsive vs adapted tumors\n# Significance and therapeutic implications","[{\"question\":\"Why have PI3K/AKT/mTOR pathway inhibitors been ineffective in TNBC clinical trials?\",\"answer\":\"Adaptive drug resistance has limited clinical efficacy, driven largely by transcriptomic plasticity in TNBC that enables transcriptional adaptation to therapy.\"},{\"question\":\"What is the main effect of CDK8/19 inhibitors on TNBC models in vivo versus in vitro?\",\"answer\":\"All tested TNBC human models responded to CDK8/19 inhibitors in vivo, including patient-derived xenografts, even when they did not respond in vitro.\"},{\"question\":\"How do CDK8/19 inhibitors interact with mTOR and AKT inhibitors?\",\"answer\":\"CDK8/19 inhibitors synergized with everolimus (mTORC1 inhibitor) and potentiated tumor suppression with capivasertib (pan-AKT inhibitor) in long-term in vivo studies.\"},{\"question\":\"What did transcriptomic analyses reveal about drug adaptation and combination mechanisms?\",\"answer\":\"Drug adaptation to everolimus in vivo was associated with major transcriptional changes in both tumor and stromal cells, and combining everolimus with a CDK8/19 inhibitor counteracted many of these changes with combination-specific gene expression effects.\"}]","Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors - Research article | PDF",1790036861,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/812554b300a9f5cda0a7206c8aaf5ac5.webp",983,1316,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cdeed3221fba729f1cc6376c17900cc.webp",982,1315,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f658f8a8b6f605446b954e10ba2a1d79.webp",981,1313,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2fd74d2519ce6c7c4054d204c1ad7c0.webp",980,1312]